IZERVAY is contraindicated in patients with ocular or periocular infections and in patients
with active intraocular inflammation.
Warnings and Precautions
- Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with
endophthalmitis and retinal
detachments. Proper aseptic injection technique must always be used when administering
IZERVAY in order to
minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of
endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular
choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12.
receiving IZERVAY should be monitored for signs of neovascular AMD.
Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection,
IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and
- Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were
conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic
atrophy (GA) secondary to age-related macular degeneration (AMD)